INAB · IN8bio Inc
United States · RS rating 29 · As of 2026-10-14
| Price | 1.20 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 29 / 95 / 27 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 8 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +3.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.7% |
| Market cap (USD) | $14.0M |